{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03003364",
      "OrgStudyIdInfo": {
        "OrgStudyId": "XCEL-SCI-01"
      },
      "Organization": {
        "OrgFullName": "Banc de Sang i Teixits",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury",
      "OfficialTitle": "A Phase I/IIa, Randomized, Double-blind, Single-dose, Placebo Controlled, Two-way Crossover Clinical Trial to Assess the Safety and to Obtain Efficacy Data in Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2020",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 27, 2016",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 25, 2019",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "February 11, 2020",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "December 14, 2016",
      "StudyFirstSubmitQCDate": "December 21, 2016",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 28, 2016",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "February 13, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 17, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Banc de Sang i Teixits",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Hospital de Neurorehabilitació Institut Guttmann",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Recerca Clínica S.L.",
            "CollaboratorClass": "INDUSTRY"
          },
          {
            "CollaboratorName": "Syntax for Science, S.L",
            "CollaboratorClass": "INDUSTRY"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a phase I/IIa, randomized, double-blind, two-arms, two-dose administration, placebo controlled, two-way crossover clinical trial in which 10 patients from 18 to 65 years of age affected with chronic traumatic spinal cord will enter the study with the objective to assess the safety and to obtain efficacy data in intrathecal administration of expanded Wharton's jelly mesenchymal stem cells.",
      "DetailedDescription": "This is a phase I/IIa, randomized, double-blind, two-arms, two-dose administration, placebo controlled, clinical trial in which 10 patients from 18 to 65 years of age affected with chronic traumatic spinal cord will enter the study with the objective to assess the safety and to obtain efficacy data in intrathecal administration (L3 level) of expanded Wharton's jelly mesenchymal stem cells. Following the administration patients will remain for 24 h at the hospital and thereafter will be discharged. For the first period, the follow-up is planned at day 7 and at 1, 3 and 6 months. At month 6, the patients will be treated in a crossover way (second period) and will follow the same schedule for the follow-up. First clinical trial evaluation will be performed at 12 month follow-up. From 12 to 18 month after the first infusion, patients will be randomized again to active treatment or placebo (double-blind) in order to assess the safety and efficacy of a second dose at 12 month follow-up. Thereafter, patients will be followed up at 24 and 36 months as part of a long-term follow-up."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Spinal Cord Injury, Chronic"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Crossover Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Quadruple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "10",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "XCEL-UMC-BETA/placebo",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: XCEL-UMC-BETA",
                "Drug: Placebo"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo/XCEL-UMC-BETA",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: XCEL-UMC-BETA",
                "Drug: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "XCEL-UMC-BETA",
            "InterventionDescription": "Intrathecal allogeneic cell therapy in a blinded syringe",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo/XCEL-UMC-BETA",
                "XCEL-UMC-BETA/placebo"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Expanded MSC from Wharton Jelly"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Placebo",
            "InterventionDescription": "Placebo in a blinded syringe",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo/XCEL-UMC-BETA",
                "XCEL-UMC-BETA/placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Incidence of treatment-emergent adverse events",
            "PrimaryOutcomeDescription": "Adverse events",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Extent and severity of a patient's spinal cord injury",
            "SecondaryOutcomeDescription": "ASIA Impairment Scale",
            "SecondaryOutcomeTimeFrame": "6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Motor electrophysiology assessment",
            "SecondaryOutcomeDescription": "Evoked potentials",
            "SecondaryOutcomeTimeFrame": "6 month"
          },
          {
            "SecondaryOutcomeMeasure": "Somatosensory electrophysiology assessment",
            "SecondaryOutcomeDescription": "Evoked potentials",
            "SecondaryOutcomeTimeFrame": "6 month"
          },
          {
            "SecondaryOutcomeMeasure": "Electrical nerve stimulation on pain perception",
            "SecondaryOutcomeDescription": "Pain threshold perception",
            "SecondaryOutcomeTimeFrame": "6 month"
          },
          {
            "SecondaryOutcomeMeasure": "Mictional dysfunction",
            "SecondaryOutcomeDescription": "Urodynamic testing",
            "SecondaryOutcomeTimeFrame": "6 month"
          },
          {
            "SecondaryOutcomeMeasure": "Anal sphincter integrity",
            "SecondaryOutcomeDescription": "Anorectal manometry test",
            "SecondaryOutcomeTimeFrame": "6 month"
          },
          {
            "SecondaryOutcomeMeasure": "Neuropathic pain",
            "SecondaryOutcomeDescription": "Numerical scale (0 to 10)",
            "SecondaryOutcomeTimeFrame": "6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Spasticity",
            "SecondaryOutcomeDescription": "Modified Ashworth scale",
            "SecondaryOutcomeTimeFrame": "6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Functionality",
            "SecondaryOutcomeDescription": "SCIM III scale",
            "SecondaryOutcomeTimeFrame": "6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Quality of life (individual overall perception of quality of life, individual overall perception of their health, Physical health, Psychological, Social relationships, Environment)",
            "SecondaryOutcomeDescription": "WHOQOL BREF questionnaire",
            "SecondaryOutcomeTimeFrame": "6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Urinary disorder",
            "SecondaryOutcomeDescription": "Qualiveen questionnaire",
            "SecondaryOutcomeTimeFrame": "6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Size injury",
            "SecondaryOutcomeDescription": "Magnetic Resonance Imaging",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Presence of allogeneic cells",
            "SecondaryOutcomeDescription": "Chimerism in cerebrospinal fluid",
            "SecondaryOutcomeTimeFrame": "1 month"
          },
          {
            "SecondaryOutcomeMeasure": "Immunology",
            "SecondaryOutcomeDescription": "Antibodies anti-HLA in peripherical blood and in cerebrospinal fluid",
            "SecondaryOutcomeTimeFrame": "1 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nSingle spinal cord injury lesion caused by trauma\nAffected cord segments between T2 and T11, confirmed by magnetic resonance\nComplete paraplegia (ASIA A)\nChronic disease state (between 12 months and 5 years after the injury)\nPatients from 18 to 65 years of age, both sexes\nLife expectancy > 2 years\nConfidence that the patient will attend the follow-up visits.\nGiven informed consent in writing\nPatient is able to understand the study and its procedures\n\nExclusion Criteria:\n\nMechanic ventilation\nLesion affecting multiple levels\nLesion length superior to 3 spinal cord segments, assessed by magnetic resonance\nPenetrating trauma affecting the spinal cord\nPositive serology to HIV, HBV, HCV and or syphilis\nPregnant woman or without proper anticonceptive measures according to the investigator, or breath feeding\nUse of metal implants that complicates the MRI interpretation\nPlanned spinal surgery within subsequent 24 month after entering the trial\nIntrathecal medication or immunosuppressive drugs the previous 60 days.\nNeurodegenerative diseases\nSignificant abnormal laboratory tests that contraindicates patient's participation in the study.\nNeoplasia within the previous 5 years, or without complete remission\nPatient with difficulty for communicating\nParticipation in another clinical trial or treated with an investigational medicinal product the previous 60 days\nContraindication for lumbar punction\nOther pathologic conditions or circumstances that could complicate the participation of the patient in the study according to medical criteria\nThe patient does not accept to be followed-up for a period that could exceed the clinical trial length",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Joan Vidal, MD, PhD",
            "OverallOfficialAffiliation": "Hospital de Neurorehabilitació Institut Guttmann",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Hospital de Neurorehabilitació Institut Guttmann",
            "LocationCity": "Badalona",
            "LocationState": "Barcelona",
            "LocationZip": "08916",
            "LocationCountry": "Spain"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "32981857",
            "ReferenceType": "derived",
            "ReferenceCitation": "Albu S, Kumru H, Coll R, Vives J, Vallés M, Benito-Penalva J, Rodríguez L, Codinach M, Hernández J, Navarro X, Vidal J. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2021 Feb;23(2):146-156. doi: 10.1016/j.jcyt.2020.08.008. Epub 2020 Sep 25."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Blood and Tissue Bank of Catalonia",
            "SeeAlsoLinkURL": "http://bancsang.net/en_index/"
          },
          {
            "SeeAlsoLinkLabel": "Hospital de Neurorehabilitació Institut Guttmann",
            "SeeAlsoLinkURL": "http://www.guttmann.com/en"
          },
          {
            "SeeAlsoLinkLabel": "Marató TV3",
            "SeeAlsoLinkURL": "http://www.ccma.cat/tv3/marato/en/"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000013119",
            "ConditionMeshTerm": "Spinal Cord Injuries"
          },
          {
            "ConditionMeshId": "D000014947",
            "ConditionMeshTerm": "Wounds and Injuries"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000013118",
            "ConditionAncestorTerm": "Spinal Cord Diseases"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000020196",
            "ConditionAncestorTerm": "Trauma, Nervous System"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M15068",
            "ConditionBrowseLeafName": "Spinal Cord Injuries",
            "ConditionBrowseLeafAsFound": "Spinal Cord Injury",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M16837",
            "ConditionBrowseLeafName": "Wounds and Injuries",
            "ConditionBrowseLeafAsFound": "Injury",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M15067",
            "ConditionBrowseLeafName": "Spinal Cord Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21176",
            "ConditionBrowseLeafName": "Trauma, Nervous System",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC26",
            "ConditionBrowseBranchName": "Wounds and Injuries"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}